Evidence map›Paper›PMID 40890911›Full record

ArticleMolecular oncology2026

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow-up biomarkers for breast cancer.

Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nicholas RajanRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0003-2238-5143
Irina PrimacRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0001-7989-5027
Emre EtliogluRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0003-4267-1307
Laurens DebruyneMultidisciplinary Breast Clinic, Gynaecological Oncology Unit, Department of Obstetrics and Gynaecology, Antwerp University Hospital, Edegem, Belgium.
Ann JanssenRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.
Magy SallamRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0002-3040-8993
Kevin TaburyRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0002-8004-3718
Roel QuintensRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0002-4359-3403
Wiebren TjalmaMultidisciplinary Breast Clinic, Gynaecological Oncology Unit, Department of Obstetrics and Gynaecology, Antwerp University Hospital, Edegem, Belgium.ORCID https://orcid.org/0000-0002-6618-045X
Mohammed Abderrafi BenotmaneRadiobiology Unit, Nuclear Medical Applications Institute, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.ORCID https://orcid.org/0000-0002-8985-1578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) diagnostics and prognostics traditionally rely on invasive tissue biopsies, presenting limitations for large-scale screening and continuous patient monitoring. Salivary biomarkers have recently emerged as a compelling noninvasive and accessible alternative, offering significant potential for population-level screening and long-term monitoring of BC. In this study, we conducted a comprehensive salivary transcriptomic profiling of BC patients using high-throughput RNA sequencing. Our analysis captured a wide spectrum of RNA species, including mRNAs, lncRNAs, miRNAs, and snRNAs, highlighting their collective contributions in the molecular landscape of BC patient saliva. We identified robust human gene expression signatures that distinguish BC patients from healthy individuals. Importantly, we discovered RNA profiles that were differentially expressed relative to control samples, enabling the discrimination of noninvasive, invasive, and mixed histological types, as well as hormone receptor-positive molecular subtypes. These salivary markers showed substantial concordance with established tumor gene expression datasets, strengthening their potential relevance in clinical stratification. Furthermore, we identified subsets of salivary genes associated with nodal involvement and others linked to poor survival outcomes, highlighting their potential as prognostic indicators. A prospective follow-up analysis revealed a decline in the expression of several cancer-related salivary transcripts 1-year posttreatment, indicating that salivary RNA might also reflect treatment response over time. This study establishes a proof-of-concept for salivary RNA biomarkers as a versatile, accessible, and robust tool for BC diagnosis, prognosis, and follow-up, paving the way for innovative biomarker-driven strategies in oncology.

Indexed as

biomarkersbreast cancerliquid biopsylncRNAmolecular diagnostics and prognosticssalivary biomarkers

Identifiers

PMID40890911
PMCPMC12936433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.